Stocktoria
UNITED THERAPEUTICS Corp UTHR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1999-06-17
UNITED THERAPEUTICS Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B |
| R&D expense | $550.0M | $481.0M | $408.0M | $322.9M | $540.1M |
| SG&A expense | $755.8M | $709.7M | $477.1M | $482.1M | $467.0M |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M |
| Interest expense | — | — | $59.3M | $32.4M | $18.6M |
| Income tax | $379.2M | $343.9M | $289.5M | $223.3M | $118.1M |
| Net income | $1.3B | $1.2B | $984.8M | $727.3M | $475.8M |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
| Operating cash flow | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M |
| Free cash flow | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M |
| Cash & equivalents | $1.6B | $1.7B | $1.2B | $961.2M | $894.8M |
| Inventory | $183.1M | $157.9M | $111.8M | $102.0M | $93.8M |
| Total assets | $7.9B | $7.4B | $7.2B | $6.0B | $5.2B |
| Total liabilities | $783.8M | $920.0M | $1.2B | $1.2B | $1.2B |
| Shareholders' equity | $7.1B | $6.4B | $6.0B | $4.8B | $4.0B |
Source: SEC EDGAR filings · CIK 0001082554 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.